Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $143.80 USD
Change Today +1.33 / 0.93%
Volume 4.4M
AMGN On Other Exchanges
Hong Kong
Sao Paulo
As of 8:10 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/15 - $181.81
52 Week Low
10/16/14 - $127.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has strategic collaboration with Xencor, Inc.; and collaborative agreements with AstraZeneca Plc, Takeda Pharmaceutical Company Limited, UCB, Novartis AG, and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

17,900 Employees
Last Reported Date: 02/19/15
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.4M
Executive Vice President of Operations
Total Annual Compensation: $943.0K
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $899.9K
Compensation as of Fiscal Year 2014.

amgen inc (AMGN) Key Developments

Amgen, Xencor Enter into a Research and License Agreement to Develop Cancer Immunotherapy Treatments

Amgen and Xencor entered into a research and license agreement that could be worth as much as $1.7 billion to develop and commercialize therapeutics focused on cancer immunotherapy and inflammation. Under the partnership, Amgen will be in charge of preclinical and clinical development and commercialization, drawing on its background in protein therapeutics, while Xencor will contribute molecular engineering and bispecific molecules through its trademarked XmAb technology platform. The drug discovery will center on five Amgen-suggested antibody programs, and one specifically dedicated to multiple myeloma. Financially, Amgen will pay Xencor $45 million upfront and up to $1.7 billion for potential clinical, regulatory and sales milestones for six oncology programs, the companies said. Xencor could also receive royalties for developed medications and use of its CD38 bispecific T cell engager.

Amgen and Allergan Announce Positive Top-Line Results from Phase 3 Study of Biosimilar Candidate ABP 215

Amgen and Allergan plc announced a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary endpoints. The study evaluated the efficacy and safety of ABP 215 compared with Avastin (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). The primary endpoint, an assessment of objective response rates (ORR), was within the prespecified margin for ABP 215 compared to bevacizumab, showing clinical equivalence. Safety and immunogenicity of ABP 215 were comparable to bevacizumab. Secondary endpoint results were consistent with the primary finding and included risk difference of ORR, duration of response and progression-free survival (PFS). ABP 215 is being developed as a biosimilar to bevacizumab, a recombinant immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 and VEGF receptor-2, thus inhibiting establishment of new blood vessels necessary for the maintenance and growth of solid tumors. Amgen and Allergan are collaborating on the development and commercialization of four oncology biosimilars. Amgen has a total of nine biosimilars in development. Allergan is also independently developing biosimilars.

Amgen Announces U.S. Food and Drug Administration Accepts Supplemental New Drug Application

Amgen announced the U.S. Food and Drug Administration has accepted for priority review the supplemental New Drug Application of Kyprolis for Injection for patients with relapsed multiple myeloma. The sNDA is designed to expand the current indication to include Kyprolis in combination with dexamethasone for patients who have received at least one prior therapy. The Prescription Drug User Fee Act (PDUFA) target action date is January 22, 2016. The FDA's acceptance of this new sNDA for Kyprolis follows the recent FDA approval for Kyprolis in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Multiple myeloma is a rare and complex blood cancer that has historically been one of the most difficult to treat diseases because of the inherent complexities related to the recurring pattern of remission and relapse. Patients face poor outcomes, which worsen with each relapse.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $143.80 USD +1.33

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $56.68 USD +0.86
Allergan plc $278.58 USD -9.42
Bristol-Myers Squibb Co $61.97 USD -0.26
Eli Lilly & Co $86.57 USD -0.95
Medtronic PLC $70.87 USD -0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation AMGN Industry Range
Price/Earnings 18.9x
Price/Sales 5.2x
Price/Book 3.9x
Price/Cash Flow 18.6x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at